Literature DB >> 7619886

A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions.

A J Humberstone1, G J Currie, C J Porter, M J Scanlon, W N Charman.   

Abstract

The development of a new and simplified, validated LC assay for the quantitation of halofantrine and desbutylhalofantrine in plasma is described. The methodology employs an inexpensive, rapid and simple liquid-liquid extraction procedure in combination with previously reported chromatographic conditions. The method has been employed to study aspects of the pharmacokinetics of orally administered halofantrine in beagle dogs and some preliminary data are presented. During development of the extraction procedure, degradation of desbutylhalofantrine was observed under non-acidic conditions in the extraction solvent (tert-butyl methyl ether) and we also report the structural elucidation of the breakdown product and the conditions required to avoid this degradation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619886     DOI: 10.1016/0731-7085(95)01256-k

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Authors:  Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

2.  Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors:  René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

3.  The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).

Authors:  Maria Høtoft Michaelsen; Kishor M Wasan; Olena Sivak; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2016-01       Impact factor: 4.009

4.  Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.

Authors:  R Holm; A Müllertz; G P Pedersen; H G Kristensen
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

5.  Bile increases intestinal lymphatic drug transport in the fasted rat.

Authors:  Natalie L Trevaskis; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

6.  Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats.

Authors:  Ditte M Karpf; René Holm; Henning G Kristensen; Anette Müllertz
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

7.  Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.

Authors:  Shui-Mei Khoo; David M Shackleford; Christopher J H Porter; Glenn A Edwards; William N Charman
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

8.  Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice.

Authors:  Vanessa C F Mosqueira; Philippe M Loiseau; Christian Bories; Philippe Legrand; Jean-Philippe Devissaguet; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations.

Authors:  Ann Marie Kaukonen; Ben J Boyd; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.